Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9105
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrakenhoff, Sylvia M.-
dc.contributor.authorKnegt, Robert J. de-
dc.contributor.authorCampenhout, Margo J.H. van-
dc.contributor.authorEijk, Annemiek A. van der-
dc.contributor.authorBrouwer, Willem P.-
dc.contributor.authorBo¨mmel, Florian van-
dc.date.accessioned2024-12-16T03:44:21Z-
dc.date.available2024-12-16T03:44:21Z-
dc.date.issued2023-02-
dc.identifier.citationOriginal Articleen_US
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9105-
dc.description.abstractAbstract Background/Purpose(s): Since ALT flares after therapy withdrawal are associated with adverse outcomes, risk stratification is of major importance. We aimed to study whether off-treatment flares are related with virological outcomes, and if serum levels of novel biomarkers at end-of-treatment (EOT) can predict flares. Methods: Chronic hepatitis B patients who participated in three global randomised trials of peginterferon-based therapy were studied (99e01, PARC, ARES). HBV RNA, HBsAg and HBcrAg were quantified at EOT. Associations between EOT biomarker levels and flares were assessed as continuous data and after categorisation. Flares were defined as ALT 5xULN during six months after therapy cessation. Results: We included 344 patients; 230 HBeAg-positive and 114 HBeAg-negative. Patients were predominantly Caucasian (77.0%) and had genotype A/B/C/D in 23.3/7.3/13.4/52.3%. Flares were observed in 122 patients (35.5%). Flares were associated with lower rates of sustained response (3.5% vs 26.8% among patients with and without a flare; p < 0.001). Higher HBsAg (OR 1.586, 95%CI 1.231e2.043), HBV RNA (OR 1.695, 95%CI 1.371e2.094) and HBcrAg (OR 1.518, 95%CI 1.324e1.740) levels were associated with higher risk of flares (p < 0.001). Combinations of biomarkers further improved risk stratification, especially HBsAg þ HBV RNA. Findings were consistent in multivariate analysis adjusted for potential predictors including HBeAgstatus and EOT-response (HBV DNA <200 IU/mL). Conclusion: Off-treatment ALT flares were not associated with favourable virological outcomes. Higher EOT serum HBsAg, HBcrAg and HBV RNA were associated with a higher risk of flares after therapy withdrawal. These findings can be used to guide decision-making regarding therapy discontinuation and off-treatment follow-up.en_US
dc.language.isoen_USen_US
dc.publisherJournal of Microbiology, Immunology and Infectionen_US
dc.subjectHepatitis B virusen_US
dc.subjectSerum biomarkersen_US
dc.subjectLiveren_US
dc.subjectHBVen_US
dc.subjectHepatologyen_US
dc.subjectFlareen_US
dc.titleEnd-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patientsen_US
dc.typeArticleen_US
Appears in Collections:VOL 56 NO 1 2023

Files in This Item:
File Description SizeFormat 
31-39.pdf670.32 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.